Development and commercialization of a completely new class of antibiotics called Odilorhabdins is the goal behind an R&D pact between Nosopharm SAS of France and German biotech Evotec SE. Clinical trials in humans could start within two years.
Under their pact, announced 3 July, the duo will initially advance Nosopharm’s lead candidate, NOSO-502, to the clinical stage, while...








